Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Radiation Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1599853

This article is part of the Research TopicDeciphering Hidden Biology Through Mathematical Techniques for Precision Radiation OncologyView all articles

Radiomics-Based Machine Learning for Differentiating Lung Squamous Cell Carcinoma and Adenocarcinoma Using T1-Enhanced MRI of Brain Metastases

Provisionally accepted
  • 1Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Chengdu, Sichuan Province, China
  • 2Department of Targeting Therapy & Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Chengdu, Sichuan Province, China
  • 3Radiotherapy Physics and Technology Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

Objective: This study aims to develop and evaluate a radiomics-based machine learning model using T1-enhanced magnetic resonance imaging (MRI) features to differentiate between lung squamous cell carcinoma (SCC) and adenocarcinoma (AC) in patients with brain metastases (BMs). While prior studies have largely focused on primary lung tumors, our work uniquely targets metastatic brain lesions, which pose distinct diagnostic and therapeutic challenges.In this retrospective study, 173 patients with BMs from lung cancer were included, consisting of 88 with AC and 85 with SCC. MRI images were acquired using a standardized protocol, and 833 radiomic features were identified from the segmented lesions utilizing the PyRadiomics package. Feature selection was performed using a combination of univariate analysis, correlation analysis, and the least absolute shrinkage and selection operator (LASSO) regression. Ten machine learning classifiers were trained and validated utilizing the selected features. The performance of the classifier models was assessed through receiver operating characteristic (ROC) curves, and the area under the curve (AUC) was examined for analysis.Results: Ten classifier models were built on the basis of features derived from MRI.Among the ten classifier models, the LightGBM model performed the best. In the training dataset, the LightGBM classifier achieved an accuracy of 0.814, with a sensitivity of 0.726 and specificity of 0.896. The classifier's efficiency was validated on an independent testing dataset, where it maintained an accuracy of 0.779, with a sensitivity of 0.725 and specificity of 0.857. The AUC was 0.858 for the training dataset and 0.857 for the testing dataset. The model effectively distinguished between SCC and AC based on radiomic features, highlighting its potential for noninvasive non-small cell lung cancer (NSCLC) subtype classification.This research demonstrates the efficacy of a radiomics-based machine learning model in accurately classifying NSCLC subtypes from BMs, providing a valuable noninvasive tool for guiding personalized treatment strategies. Further validation on larger, multi-center datasets is crucial to verify these findings.

Keywords: Credit Author Statement: Xueming Xia: Writing -original draft Qiaoyue Tan: Supervision and Validation, Data curation Wei Du: Software, Conceptualization, Formal analysis, Methodology Qiheng Gou: Funding Acquisition, Writing -review & editing Radiomics, Magnetic Resonance Imaging, lung cancer

Received: 25 Mar 2025; Accepted: 03 Jul 2025.

Copyright: © 2025 Xia, Du, Tan and Gou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Qiheng Gou, Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Chengdu, Sichuan Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.